Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 26;6(5):100692. doi: 10.1016/j.adro.2021.100692

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 2 — Subset survival analysis of oligoprogressive patients. (A) Kaplan-Meier estimate of modified progression-free survival (mPFS) based on type of systemic therapy during stereotactic ablative radiation therapy (SAbR), including immune checkpoint inhibitors (ICIs), vascular endothelial growth factor (VEGF) inhibitors (VEGF-I), and mechanistic target of rapamycin inhibitors (mTOR-I). (B) Kaplan-Meier estimate of mPFS based on number of prior lines of systemic therapy. (C) Kaplan-Meier estimate of mPFS according to number of metastases present at time of radiation.